Drug Development

With new financing from Avenue Capital, Turn Therapeutics bets big on its novel skin therapy, GX-03, to tackle multi-billion dollar dermatology markets.

A new Phase 2 trial is testing an inhaled version of a key IPF drug, aiming to reduce severe side effects and transform treatment for the fatal lung disease.

UK biotech Amphista to showcase its innovative Targeted Glue™ platform at AACR, revealing new data for AML, lung cancer, and mesothelioma therapies.

With fresh funding secured, Dogwood Therapeutics pushes its promising nerve pain drug, Halneuron®, toward a pivotal data readout later this year.

InflaRx announces a late-breaking presentation on its Phase 3 trial for vilobelimab, offering potential new hope for pyoderma gangrenosum patients.

SAB Biotherapeutics' public offering fuels late-stage trials for its promising T1D drug, SAB-142, aiming to change the treatment landscape.

The FDA grants PolyPid a crucial $4.3 million fee waiver for its D-PLEX₁₀₀ drug, freeing up vital cash to accelerate its commercial launch.

Aldeyra Therapeutics' dry eye drug, reproxalap, was rejected by the FDA for a third time, citing inconsistent data and wiping out millions in value.

After regaining Nasdaq compliance, Incannex Healthcare is leveraging its $75M war chest to advance novel treatments for sleep apnea and anxiety.

A new collaboration will use Voro's 'masking' technology to create tumor-activated ADCs, aiming to make powerful cancer therapies safer and more effective.

Galectin Therapeutics adds legendary neurosurgeon Dr. Henry Brem to its board, a strategic move to leverage his drug development expertise for its lead liver drug.

UK biotech Alchemab hires Sanofi's Ulrich Wendt as CBO to forge major pharma deals for its novel AI platform that mines the secrets of human resilience.

As MediciNova execs meet investors at the ROTH Conference, all eyes are on pivotal updates for its ALS, MS, and NAFLD drug candidates.

A landmark review decodes how ketogenic diets treat epilepsy, highlighting a major research gap and sparking a quest for drugs that mimic the diet's effects.

Theriva Biologics pushes its promising cancer virus toward pivotal trials, but an auditor's 'going concern' warning raises questions about its future.

Ratio Therapeutics appoints Dr. Colin Hayward as CMO, a strategic move to advance its sarcoma trial and challenge leaders in the booming radiopharmaceutical market.

A new clinical trial begins for APAC, a first-in-class drug aiming to prevent amputation and death from severe peripheral artery disease.

Biotech leader H. Martin Seidel joins Odyssey's SAB, a strategic move signaling accelerated development in the competitive autoimmune disease space.

With its novel glaucoma drug QLS-111 entering Phase 3, Qlaris Bio brings in seasoned leader Fred Guerard to navigate the final trials and path to market.

Edgewise Therapeutics' drug sevasemten shows unprecedented functional stability in Becker muscular dystrophy, a pivotal shift for a disease with no treatments.